Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02447003
Title Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.